AGWCA
AMPH icon

Annis Gardner Whiting Capital Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$427 – 1214
2025
Q3 		$427 Hold
16
– – ﹤0.01% 1096
2025
Q2 		$368 Buy
+16
New +$397 ﹤0.01% 1214

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's AMPH Position: Q4 2025 in Review

Annis Gardner Whiting Capital Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2025, closing a stake of 16 shares — an estimated $427 sold.

Annis Gardner Whiting Capital Advisors first reported a position in AMPH in Q2 2025 and held it in 2 quarters. The position peaked at $427 in Q3 2025. 235 funds tracked by Wall St. Rank hold AMPH as of Q4 2025.

  • Annis Gardner Whiting Capital Advisors reported no remaining Amphastar Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 16 Amphastar Pharmaceuticals shares in Q4 2025, an estimated $427.
  • Annis Gardner Whiting Capital Advisors first reported a position in Amphastar Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Amphastar Pharmaceuticals position peaked at $427 in Q3 2025.
  • 235 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2025.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.